scispace - formally typeset
Search or ask a question
Journal ArticleDOI

The multifunctional role of filaggrin in allergic skin disease

01 Feb 2013-The Journal of Allergy and Clinical Immunology (J Allergy Clin Immunol)-Vol. 131, Iss: 2, pp 280-291
TL;DR: In this article, the authors discuss the mechanisms through which mutations in the human filaggrin gene contribute to the pathogenesis of atopic dermatitis and associated atopic conditions.
Abstract: Filaggrin is a major structural protein in the stratum corneum of the epidermis. Mutations in the filaggrin gene are the most significant known genetic risk factor for the development of atopic dermatitis. Mutations in the human filaggrin gene (FLG) also confer risk for the associated allergic diseases of food allergy, asthma, and allergic rhinitis. These discoveries have highlighted the importance of skin barrier function in the pathogenesis of atopic diseases and have motivated a surge in research characterizing the filaggrin-deficient skin barrier and its consequences. In this review we discuss the mechanisms through which mutations in this protein contribute to the pathogenesis of atopic dermatitis and associated atopic conditions. We focus on recent human and murine discoveries characterizing the filaggrin-deficient epidermis with respect to biophysical, immunologic, and microbiome abnormalities.

Summary (1 min read)

Introduction

  • (2, 3) It is the most common chronic inflammatory disease of early childhood (4) and is associated with significant morbidity for the patient and their families.
  • T helper (Th2) cell response, and frequent Staphylococcus aureus colonization.
  • (4) It is often the initial step in the so called 'atopic march', with the subsequent development of allergies, asthma and hay fever.
  • Mutations in the FLG gene, which codes for the skin barrier protein filaggrin, have been shown to be the most significant risk factor, to date, for developing AD.
  • (4) The specific dynamic interactions between an impaired skin barrier and the immune system remain to be fully elucidated.

Epidermal Structure and Function: Role of Filaggrin

  • The epidermis, particularly the outermost stratum corneum (SC) layer, is the first line of defense between the host organism and its environment.
  • (9, 10) Filaggrin is a major structural protein in the SC.
  • (4) The role of filaggrin in epidermal structure and function has been reviewed in detail in recent papers.
  • A significant number of patients with AD do not have any of the known FLG mutations, and conversely, approximately 40% of individuals with FLG null alleles do not develop AD. (31) (40).
  • Some studies have investigated putative environmental risk factors for atopic disease genotype with regards to FLG status.

Characterization of filaggrin deficient skin barrier function.

  • The barrier integrity phenotype associated with FLG mutations is becoming better understood, with human and murine studies supporting the theory that FLG mutations lead to a functional epidermal barrier defect and subsequent allergic sensitization.
  • FLG genotype has been shown to be the major determinant of NMF in human studies.
  • The cytokines involved in the pathogenesis of AD, similar to other inflammatory skin diseases, are multiple and complex and much work will be needed to clarify these pathways.
  • (121) These data suggest that SEB plays an important role in Ova-induced lung inflammation and airway hyperresponsiveness via an IL-17A-dependent pathway.
  • Filaggrin's protective effect against alpha toxin was via mediation of sphingomyelinase secretion, an enzyme that reduces the number of alpha toxin binding sites on the cell surface.

Conclusion

  • The pathomechanisms of AD are complex and include both structural abnormalities and immunological dysregulation.
  • This has directed the development skin barrier focused therapies.
  • Excluding null mutations, the number of filaggrin units in humans, termed filaggrin copy number variation (CNV), varies from 20 to 24.
  • Keratinocytes cultured with IL-17A also resulted in a significant decrease in profilaggrin mRNA levels and filaggrin protein expression.
  • In the setting of AD FLG , the combination of genetically determined and acquired filaggrin insufficiency may lead to a greater and more prolonged filaggrin downregulation.

Did you find this useful? Give us your feedback

Content maybe subject to copyright    Report

1
The Multifunctional Role of Filaggrin in Allergic Skin Disease 1
2
Authors 3
Maeve A McAleer, MRCP
1,2, 3
& Alan D Irvine, MD
1,2,3
4
5
Affiliations 6
1. National Children’s Research Centre 7
Our Lady’s Children’s Hospital, Crumlin, Dublin 8
2. Department of Pediatric Dermatology 9
Our Lady’s Children’s Hospital, Crumlin, Dublin 10
3. Department of Clinical Medicine, 11
Trinity College Dublin. 12
13
Corresponding Author: 14
Alan D Irvine, 15
The Department of Paediatric Dermatology 16
Our Lady’s Children’s Hospital, Crumlin 17
Dublin 12, IRELAND 18
Email: irvinea@tcd.ie 19
Telephone: +3531 428 2532 20
21
Sources of Funding: National Children’s Research Centre, Dublin 22
Conflicts of interest: none 23
24

2
25
Abstract 26
Filaggrin is a major structural protein in the stratum corneum of human epidermis. 27
Mutations in the filaggrin gene are the most significant known risk factor for the 28
development of atopic dermatitis. Mutations in
FLG
also confer risk for the associated 29
allergic diseases of food allergy, asthma, and allergic rhinitis. These discoveries have 30
highlighted the importance of skin barrier function in the pathogenesis of atopic 31
diseases and have motivated a surge in research characterizing the filaggrin deficient 32
skin barrier and its consequences. In this review we discuss the mechanisms through 33
which mutations in this protein contribute to the pathogenesis of atopic dermatitis 34
and associated atopic conditions. We focus on recent human and murine discoveries 35
characterizing the filaggrin deficient epidermis with respect to biophysical, 36
immunological and microbiome abnormalities. 37
38
Abstract word count: 12639

3
List of Key words 40
Filaggrin, atopy, dermatitis, eczema, IL-1β 41
Abbreviations 42
AD: atopic dermatitis, AMP: antimicrobial peptide, ASC: apoptosis-associated speck-43
like protein, CNV: copy number variation,
FLG
: human filaggrin gene,
Flg
: murine 44
filaggrin gene, IgE: immunoglobin E, IsdA: iron-regulated surface determinant A, 45
LEKTI: Lympho-epithelial Kazal-type-related inhibitor, NMF: natural moisturizing 46
factor. NLRP3: nucleotide-binding oligomerisation leucine-rich repeat and pyrin 47
domain containing 3, OR: odds ratio, OVA: ovalbumin, PAC: pyrroliodine-5-carboxylic 48
acid, PBMC: peripheral blood mononucleocyte, SEB: Staphlococcal enterotoxin B, 49
Staph aureus: Staphlococcus aureus
, SpA: Staphlococcus protein A, SC: stratum 50
corneum, Th: T helper, TEWL: transepidermal water loss, TJ: tight junction, UCA: 51
trans-urocanic acid, US: United States, UK: United Kingdom. 52
Following standard genetic practice, in this paper
FLG
-/- designates a patient 53
homozygous for null alleles (i.e. 2 null alleles);
FLG
+/- a heterozygote null 54
allele/ wildtype (i.e. one null allele) and
FLG
+/+ a homozygote wildtype (i.e. 55
0 null alleles). A further abbreviation describes AD patients with
FLG
56
mutations (
FLG
+/- and
FLG
-/-) as AD
FLG
and those without
FLG
mutations 57
(i.e.
FLG
+/+) as AD
NON-FLG
.
58
59
Main text word count: 5556 60
61

4
Introduction 62
Atopic dermatitis (AD) affects approximately 11% of children in the US (1) and up to 63
25% in the UK. (2, 3) It is the most common chronic inflammatory disease of early 64
childhood (4) and is associated with significant morbidity for the patient and their 65
families. (5) Atopic dermatitis is characterized by an epidermal barrier abnormality, 66
cutaneous inflammation, immune dysregulation with a systemic ‘allergic’ T helper 67
(Th2) cell response, and frequent
Staphylococcus aureus
colonization.(4) It is often 68
the initial step in the so called ‘atopic march’, with the subsequent development of 69
allergies, asthma and hay fever.(6) The critical importance of the epithelium in the 70
development of AD and allergic sensitisation has become apparent. Mutations in the 71
FLG
gene, which codes for the skin barrier protein filaggrin, have been shown to be 72
the most significant risk factor, to date, for developing AD.(4) The specific dynamic 73
interactions between an impaired skin barrier and the immune system remain to be 74
fully elucidated. Here we review recent insights into the role of filaggrin in the 75
pathomechanisms of AD and its associated diseases. 76
Epidermal Structure and Function: Role of Filaggrin 77
The epidermis, particularly the outermost stratum corneum (SC) layer, is the first line 78
of defense between the host organism and its environment. The SC also minimizes 79
water loss from the body and protects against both every day and extreme 80
environmental insults. (7) The SC is the end product of a highly organized 81
differentiation process in which keratinocytes in the basal layer of the epidermis 82
progress to form the spinous and granular layers, ultimately forming a tough 83
multilayer of corneocytes rich in intracellular lipids. (7) The SC matrix is an 84
extensively cross-linked lipid protein matrix organized into neutral, lipid enriched, 85
extracellular lamellar bilayers.(8) This hydrophobic extracellular matrix, together with 86

5
corneodesmosomes and tight junctions, specialized cohesive intercellular junctions in 87
the stratum corneum and stratum granulosum, forms a very effective barrier.(9, 10) 88
Filaggrin is a major structural protein in the SC. (4) The role of filaggrin in epidermal 89
structure and function has been reviewed in detail in recent papers. (4, 7, 11) 90
Filaggrin is produced as the precursor pro-protein profilaggrin. Profilaggrin is 91
expressed in terminally differentiating keratinocytes in the outmost layers of the 92
human epidermis and is the major constituent of keratohyalin granules in the 93
stratum granulosum. (7) Profilaggrin consists of multiple filaggrin repeats flanked by 94
an S100-type calcium-binding domain, A and B domains at the N-terminal, and a 95
unique tail sequence at the C terminal [Figure 1a](4)] 96
During terminal differentiation at the granular to cornified layer transition, 97
profilaggrin is rapidly dephosphorylayed and cleaved by several endoproteases to 98
generate 10,11 or 12 functional filaggrin monomers. (12) Extracellular proteases, 99
such as matriptase, may also influence the expression of filaggrin monomers.(13) 100
Filaggrin monomers aggregate and align keratin bundles,
in vitro
, and are thus 101
postulated to contribute to the mechanical strength and integrity of the SC
in vivo.
102
(14) [Figure 1a] Ultrastructural studies have shown that filaggrin deficiency results in 103
disorganized keratin filaments, impaired lamellar body loading, and abnormal 104
architecture of the lamellar bilayer.(10) [Figure 1b] It has been proposed that
FLG
N-105
terminal provides a feedback mechanism that controls epidermal homeostasis.(15) 106
The C-terminal domain’s exact function is unclear but it is necessary for profilaggrin 107
to filaggrin processing. Truncated profilaggrin, lacking a C-terminal, results in almost 108
a complete absence of filaggrin.(12) 109
In the upper layers of the SC, filaggrin monomers are deiminated and degraded by 110
proteases to release their component hygroscopic amino acids and their derivatives. 111

Citations
More filters
Journal ArticleDOI
TL;DR: It is demonstrated that emollient therapy from birth represents a feasible, safe, and effective approach for atopic dermatitis prevention and would be a simple and low-cost intervention that could reduce the global burden of allergic diseases.
Abstract: Background Atopic dermatitis (atopic eczema) is a chronic inflammatory skin disease that has reached epidemic proportions in children worldwide and is increasing in prevalence. Because of the significant socioeconomic effect of atopic dermatitis and its effect on the quality of life of children and families, there have been decades of research focused on disease prevention, with limited success. Recent advances in cutaneous biology suggest skin barrier defects might be key initiators of atopic dermatitis and possibly allergic sensitization. Objective Our objective was to test whether skin barrier enhancement from birth represents a feasible strategy for reducing the incidence of atopic dermatitis in high-risk neonates. Methods We performed a randomized controlled trial in the United States and United Kingdom of 124 neonates at high risk for atopic dermatitis. Parents in the intervention arm were instructed to apply full-body emollient therapy at least once per day starting within 3 weeks of birth. Parents in the control arm were asked to use no emollients. The primary feasibility outcome was the percentage of families willing to be randomized. The primary clinical outcome was the cumulative incidence of atopic dermatitis at 6 months, as assessed by a trained investigator. Results Forty-two percent of eligible families agreed to be randomized into the trial. All participating families in the intervention arm found the intervention acceptable. A statistically significant protective effect was found with the use of daily emollient on the cumulative incidence of atopic dermatitis with a relative risk reduction of 50% (relative risk, 0.50; 95% CI, 0.28-0.9; P = .017). There were no emollient-related adverse events and no differences in adverse events between groups. Conclusion The results of this trial demonstrate that emollient therapy from birth represents a feasible, safe, and effective approach for atopic dermatitis prevention. If confirmed in larger trials, emollient therapy from birth would be a simple and low-cost intervention that could reduce the global burden of allergic diseases.

569 citations

Journal ArticleDOI
TL;DR: Recent studies support the idea of a causal link between AD and later onset atopic disorders and suggest that a dysfunctional skin barrier serves as a site for allergic sensitization to antigen and colonization of bacterial super antigens.
Abstract: The development of atopic dermatitis (AD) in infancy and subsequent allergic rhinitis and asthma in later childhood is known as the atopic march. This progressive atopy is dependent on various underlying factors such as the presence of filaggrin mutations as well as the time of onset and severity of AD. Clinical manifestations vary among individuals. Previously it was thought that atopic disorders may be unrelated with sequential development. Recent studies support the idea of a causal link between AD and later onset atopic disorders. These studies suggest that a dysfunctional skin barrier serves as a site for allergic sensitization to antigens and colonization of bacterial super antigens. This induces systemic Th2 immunity that predisposes patients to allergic nasal responses and promotes airway hyper reactivity. While AD often starts early in life and is a chronic condition, new research signifies that there may be an optimal window of time in which targeting the skin barrier with therapeutic interventions may prevent subsequent atopic disorders. In this review we highlight recent studies describing factors important in the development of atopic disorders and new insights in our understanding of the pathogenesis of the atopic march.

500 citations

Journal ArticleDOI
TL;DR: Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor α-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players.
Abstract: Atopic dermatitis (AD) is a complex skin disease frequently associated with other diseases of the atopic diathesis. Recent evidence supports the concept that AD can also recognize other comorbidities, such as chronic inflammatory bowel or cardiovascular diseases. These comorbidities might result from chronic cutaneous inflammation or from a common, yet-to-be-defined immunologic background leading to immune deviations. The activation of immune cells and their migration to the skin play an essential role in the pathogenesis of AD. In patients with AD, an underlying immune deviation might result in higher susceptibility of the skin to environmental factors. There is a high unmet medical need to define immunologic endotypes of AD because it has significant implications on upcoming stratification of the phenotype of AD and the resulting targeted therapies in the development of precision medicine. This review article emphasizes studies on environmental factors affecting AD development and novel biological agents used in the treatment of AD. Best evidence of the clinical efficacy of novel immunologic approaches using biological agents in patients with AD is available for the anti-IL-4 receptor α-chain antibody dupilumab, but a number of studies are currently ongoing with other specific antagonists to immune system players. These targeted molecules can be expressed on or drive the cellular players infiltrating the skin (eg, T lymphocytes, dendritic cells, or eosinophils). Such approaches can have immunomodulatory and thereby beneficial clinical effects on the overall skin condition, as well as on the underlying immune deviation that might play a role in comorbidities. An effect of these immunologic treatments on pruritus and the disturbed microbiome in patients with AD has other potential consequences for treatment.

437 citations

Journal ArticleDOI
TL;DR: Current understanding of the AD immune map in both patients with early-onset and those with chronic disease is discussed, with a focus on a systemic treatment approach in patients with moderate-to-severe disease.
Abstract: Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by both terminal keratinocyte differentiation defects and strong type 2 immune responses. In contrast to chronic plaque-type psoriasis, AD is now understood to be a much more heterogeneous disease, with additional activation of TH22, TH17/IL-23, and TH1 cytokine pathways depending on the subtype of the disease. In this review we discuss our current understanding of the AD immune map in both patients with early-onset and those with chronic disease. Clinical studies with broad and targeted therapeutics have helped to elucidate the contribution of various immune axes to the disease phenotype. Importantly, immune activation extends well beyond lesional AD because nonlesional skin and the blood component harbor AD-specific inflammatory changes. For this reason, future therapeutics will need to focus on a systemic treatment approach, especially in patients with moderate-to-severe disease.

417 citations

Journal ArticleDOI
TL;DR: Prevention of atopic dermatitis can be achieved through early interventions to protect the skin barrier and reduce the systemic allergen sensitization that leads to associated allergic diseases in the gastrointestinal and respiratory tract.
Abstract: Atopic dermatitis (AD) is the most common chronic inflammatory skin disease. It often precedes the development of food allergy and asthma. Recent insights into AD reveal abnormalities in terminal differentiation of the epidermal epithelium leading to a defective stratum corneum, which allows enhanced allergen penetration and systemic IgE sensitization. Atopic skin is also predisposed to colonization or infection by pathogenic microbes, most notably Staphylococcus aureus and herpes simplex virus. Causes of this abnormal skin barrier are complex and driven by a combination of genetic, environmental, and immunologic factors. These factors likely account for the heterogeneity of AD onset and the severity and natural history of this skin disease. Recent studies suggest prevention of AD can be achieved through early interventions to protect the skin barrier. Onset of lesional AD requires effective control of local and systemic immune activation for optimal management. Early intervention might improve long-term outcomes for AD and reduce the systemic allergen sensitization that leads to associated allergic diseases in the gastrointestinal and respiratory tract.

353 citations

References
More filters
Journal ArticleDOI
TL;DR: The rise in prevalence of symptoms in many centres is concerning, but the absence of increases in prevalence in asthma symptoms for centres with existing high prevalence in the older age-group is reassuring.

3,762 citations

Journal ArticleDOI
TL;DR: The IL-1 family includes members that suppress inflammation, both specifically within the IL-2 family but also nonspecifically for TLR ligands and the innate immune response.
Abstract: More than any other cytokine family, the interleukin (IL)-1 family is closely linked to the innate immune response. This linkage became evident upon the discovery that the cytoplasmic domain of the IL-1 receptor type I is highly homologous to the cytoplasmic domains of all Toll-like receptors (TLRs). Thus, fundamental inflammatory responses such as the induction of cyclooxygenase type 2, increased expression of adhesion molecules, or synthesis of nitric oxide are indistinguishable responses of both IL-1 and TLR ligands. Both families nonspecifically affect antigen recognition and lymphocyte function. IL-1β is the most studied member of the IL-1 family because of its role in mediating autoinflammatory diseases. Although the TLR and IL-1 families evolved to assist in host defense against infection, unlike the TLR family, the IL-1 family also includes members that suppress inflammation, both specifically within the IL-1 family but also nonspecifically for TLR ligands and the innate immune response.

3,032 citations

Journal ArticleDOI
TL;DR: It is shown that two independent loss-of-function genetic variants (R510X and 2282del4) in the gene encoding filaggrin (FLG) are very strong predisposing factors for atopic dermatitis.
Abstract: Atopic disease, including atopic dermatitis (eczema), allergy and asthma, has increased in frequency in recent decades and now affects approximately 20% of the population in the developed world. Twin and family studies have shown that predisposition to atopic disease is highly heritable. Although most genetic studies have focused on immunological mechanisms, a primary epithelial barrier defect has been anticipated. Filaggrin is a key protein that facilitates terminal differentiation of the epidermis and formation of the skin barrier. Here we show that two independent loss-of-function genetic variants (R510X and 2282del4) in the gene encoding filaggrin (FLG) are very strong predisposing factors for atopic dermatitis. These variants are carried by approximately 9% of people of European origin. These variants also show highly significant association with asthma occurring in the context of atopic dermatitis. This work establishes a key role for impaired skin barrier function in the development of atopic disease.

2,605 citations

Journal ArticleDOI
TL;DR: It is shown that human thymic stromal lymphopoietin (TSLP) potently activated CD11c+ dendritic cells (DCs) and induced production of the TH2-attracting chemokines TARC (thymus and activation-regulated chemokine) and MDC (macrophage-derivedChemokine; CCL22).
Abstract: Whether epithelial cells play a role in triggering the immune cascade leading to T helper 2 (T(H)2)-type allergic inflammation is not known. We show here that human thymic stromal lymphopoietin (TSLP) potently activated CD11c(+) dendritic cells (DCs) and induced production of the T(H)2-attracting chemokines TARC (thymus and activation-regulated chemokine; also known as CCL17) and MDC (macrophage-derived chemokine; CCL22). TSLP-activated DCs primed naive T(H) cells to produce the proallergic cytokines interleukin 4 (IL-4), IL-5, IL-13 and tumor necrosis factor-alpha, while down-regulating IL-10 and interferon-gamma. TSLP was highly expressed by epithelial cells, especially keratinocytes from patients with atopic dermatitis. TSLP expression was associated with Langerhans cell migration and activation in situ. These findings shed new light on the function of human TSLP and the role played by epithelial cells and DCs in initiating allergic inflammation.

1,980 citations

Related Papers (5)
Frequently Asked Questions (1)
Q1. What are the contributions in this paper?

In this review the authors discuss the mechanisms through 33 which mutations in this protein contribute to the pathogenesis of atopic dermatitis 34 and associated atopic conditions.